Antibody, Genomics, In-Vitro and Research - Clinical Research Informer

Researchers Discover Genetic Errors and Rogue Antibodies in Cases of Severe COVID-19 Infection

XTalks

SEPTEMBER 30, 2020

While it remains unclear why some people become more gravely ill than others when infected with the SARS-CoV-2 virus that causes COVID-19, researchers have found that an immune deficiency may be part of it. Two recent studies have shown that individuals who lack an important immune factor may have reduced ability to fight the virus.

Antibody

Antibody Genetics Research In-Vitro

News from AACR 2024: Sunday’s highlights

Drug Discovery World

APRIL 8, 2024

The American Association of Cancer Research (AACR) Annual Meeting launched on Sunday 7 April in San Diego with an Opening Plenary Session showcasing cutting-edge technological advances opening new frontiers in cancer science.

In-Vivo

In-Vivo In-Vitro Antibody Protein

Conversations from ESMO Targeted Anticancer Therapies Congress 2024

Drug Discovery World

MARCH 26, 2024

For example, progress made in developing gene mutant-specific inhibitors, antibody-drug conjugates (ADC), or cellular therapies. We were there to present the latest findings from our research. MT: What’s next for STORM’s research? MT: What data did you present at the conference?

RNA

RNA In-Vivo In-Vitro DNA

How T Cell Tests Could Trump Antibody Tests in the Detection of COVID-19

XTalks

NOVEMBER 20, 2020

A new type of test based on detection of activated T cells may prove to have greater utility in determining whether someone has had a COVID-19 infection compared to a traditional antibody test. Researchers at Adaptive Biotechnologies compared T-Detect to a commercial antibody test from DiaSorin on samples obtained from people in Vo’, Italy.

Antibody

Antibody Immune Response Protein In-Vitro

What to expect from PEGS Europe 2023: Day 1

Drug Discovery World

NOVEMBER 8, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting.

Antibody

Antibody Engineer Protein Scientist

Roche’s anti-amyloid beta antibody gantenerumab granted FDA Breakthrough Therapy Designation in Alzheimer’s disease

The Pharma Data

OCTOBER 9, 2021

Roche (SIX RO, ROG; OTCQX RHHBY) now posted that gantenerumab, ananti-amyloid beta antibody developed for subcutaneous administration, has been granted Improvement Rectifier Designation by theU.S. Food and Drug Administration (FDA) for the treatment of people living with Alzheimer’s fever ( Notice).

Antibody

Antibody In-Vitro Trials Development

Nine new industry collaborations driving drug discovery forward

Drug Discovery World

MAY 29, 2024

SpyBiotech and the University of Oxford Biotechnology company SpyBiotech and University of Oxford have entered a research agreement for the development of a vaccine against Epstein-Barr virus (EBV). ERS Genomics and IRBM ERS Genomics and IRBM have signed an agreement granting IRBM access to ERS’ CRISPR/Cas9 patent portfolio.

Drugs

Drugs Gene Editing Life Science Genome

Roche’s anti-amyloid beta antibody gantenerumab granted FDA Breakthrough Therapy Designation in Alzheimer’s disease

The Pharma Data

OCTOBER 14, 2021

Roche announced that gantenerumab, an anti-amyloid beta antibody developed for subcutaneous administration, has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of people living with Alzheimer’s disease (AD).

Antibody

Antibody Medicine In-Vitro Trials

Roche to present new pivotal data at ASH 2021 from broad and comprehensive portfolio, challenging treatment standards for people with blood disorders

The Pharma Data

NOVEMBER 23, 2021

1 POLARIX is being conducted in collaboration with The Lymphoma Study Association (LYSA) and The Lymphoma Academic Research Organisation (LYSARC). Roche moment blazoned that new data from its expansive haematology portfolio will be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition from 11-14 December 2021.

Antibody

Antibody In-Vitro Development Genome

Can vertical AI advance cell and gene therapies?

Drug Discovery World

DECEMBER 8, 2023

These successes and learnings provide a solid foundation for AI’s recent shift into more complex and newer drug development applications, such as monoclonal antibodies and cell and gene therapies. Andrew Busey , Co-Founder, Form Bio discusses why vertical AI is set to reshape the cell and gene therapy sector.

Gene Therapy

Gene Therapy Gene In-Vitro Development

What to expect from SLAS Europe 2023

Drug Discovery World

APRIL 21, 2023

Atrandi Biosciences’ novel technology platform enables researchers to gain insights into the biology of single cells, offering immediate applications in single-cell sequencing, drug and antibody discovery, functional metagenomics, microbial analysis, directed evolution, and synthetic biology.

Doctors

Doctors Doctor Genetics In-Vitro

Emergency Use Authorization request to FDA for VIR-7831 for the early treatment of COVID-19

The Pharma Data

MARCH 26, 2021

The FDA EUA submission is based on an interim analysis of efficacy and safety data from the Phase 3 COMET-ICE (COVID-19 Monoclonal antibody Efficacy Trial – Intent to Care Early) trial, which evaluated VIR-7831 as monotherapy for the early treatment of COVID-19 in adults at high risk of hospitalisation.

Antibody

Antibody Trials Vaccination Vaccine

Roche launches SARS-CoV-2 variant test to help monitor emerging coronavirus mutations

The Pharma Data

MARCH 16, 2021

The test runs on widely used high-throughput systems and is for research purposes only. 1 lineage gained prominence in late 2020, with each carrying a number of genomic mutations. The cobas SARS-CoV-2 Variant Set 1 Test is designed to detect key spike mutations in virus variants associated with increased human-to-human transmission.

Antibody

Antibody Clinical Trials Clinical Trials Vaccination

Clinical Catch-Up: January 18-22 | BioSpace

The Pharma Data

JANUARY 24, 2021

It will be run through the NIAID-supported Infectious Diseases Clinical Research Consortium (IDCRC), with support from the Bill & Melinda Gates Foundation. Brilacidin has shown in vitro to be have antiviral properties against different SARS-CoV-2 strains and other human coronaviruses. It also has robust antimicrobial properties.

Trials

Trials Allergies In-Vitro Antibody

Japan becomes first country to approve Ronapreve (casirivimab and imdevimab) for the treatment of mild to moderate COVID-19

The Pharma Data

JULY 23, 2021

The antibody combination was granted a Special Approval Pathway under article 14-3 of the Pharmaceuticals and Medical Devices Act. Ronapreve is a combination of two monoclonal antibodies (also known as REGN10933 and REGN10987, respectively) and was designed to block infectivity of SARS-CoV-2, the virus that causes COVID-19.

Antibody

Antibody Medicine Production In-Vitro

The Utility of Liquid Biopsy in Oncology Clinical Trials

XTalks

NOVEMBER 7, 2022

These tumor-derived entities are used to derive genomic and proteomic data. Liquid biopsy tests in oncology involve isolating entities such as circulating tumor cells (CTC), circulating tumor DNA (ctDNA) and tumor-derived exosomes. The same webinar held a Q&A session with Dr. Bahassi and two other experts from Medpace, Dr. Lyon L.

Clinical Trials

Clinical Trials Clinical Trials Trials FDA Approval

Roche’s Actemra/RoActemra receives U.S. FDA Emergency Use Authorization for the treatment of COVID-19 in hospitalised adults and children

The Pharma Data

JUNE 26, 2021

The RECOVERY Actemra/RoActemra study was led by researchers in the United Kingdom and included more than 4,000 hospitalised COVID-19 patients. The RECOVERY Actemra/RoActemra study was led by researchers in the United Kingdom and included more than 4,000 hospitalised COVID-19 patients. Actemra/RoActemra has not been approved by the U.S.

Clinical Trials

Clinical Trials Clinical Trials In-Vitro Antibody

Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020

The Pharma Data

SEPTEMBER 16, 2020

New and updated data from across our broad cancer portfolio including phase III results in breast, lung and prostate cancers. New integrated analyses from our tumour agnostic Rozlytrek ® (entrectinib) clinical development programme. Join this event on Roche’s LinkedIn page here. Roche highlights featured at ESMO Virtual Congress 2020.

HR

HR Medicine Hormones Trials

Clinical Research Informer

Researchers Discover Genetic Errors and Rogue Antibodies in Cases of Severe COVID-19 Infection

News from AACR 2024: Sunday’s highlights

Trending Sources

Conversations from ESMO Targeted Anticancer Therapies Congress 2024

How T Cell Tests Could Trump Antibody Tests in the Detection of COVID-19

What to expect from PEGS Europe 2023: Day 1

Roche’s anti-amyloid beta antibody gantenerumab granted FDA Breakthrough Therapy Designation in Alzheimer’s disease

Nine new industry collaborations driving drug discovery forward

Roche’s anti-amyloid beta antibody gantenerumab granted FDA Breakthrough Therapy Designation in Alzheimer’s disease

Roche to present new pivotal data at ASH 2021 from broad and comprehensive portfolio, challenging treatment standards for people with blood disorders

Can vertical AI advance cell and gene therapies?

What to expect from SLAS Europe 2023

Emergency Use Authorization request to FDA for VIR-7831 for the early treatment of COVID-19

Roche launches SARS-CoV-2 variant test to help monitor emerging coronavirus mutations

Clinical Catch-Up: January 18-22 | BioSpace

Japan becomes first country to approve Ronapreve (casirivimab and imdevimab) for the treatment of mild to moderate COVID-19

The Utility of Liquid Biopsy in Oncology Clinical Trials

Roche’s Actemra/RoActemra receives U.S. FDA Emergency Use Authorization for the treatment of COVID-19 in hospitalised adults and children

Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020

Stay Connected